Dyadic International, Inc. today announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100. This marks the first-in-human use of a recombinant protein vaccine expressed by Dyadic's C1-cell... READ →
Precision Vaccinations
/ November 29th, 2023Eliminating fake vaccine news with pharmacist, nurse, and physician review.
For more articles, try our search.